Hims & Hers Health, Inc. $HIMS Shares Purchased by Securian Asset Management Inc.

Securian Asset Management Inc. raised its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 2.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,931 shares of the company’s stock after purchasing an additional 411 shares during the period. Securian Asset Management Inc.’s holdings in Hims & Hers Health were worth $744,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Pinnacle Wealth Management LLC raised its holdings in shares of Hims & Hers Health by 198.7% in the 2nd quarter. Pinnacle Wealth Management LLC now owns 44,650 shares of the company’s stock worth $2,226,000 after purchasing an additional 29,704 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Hims & Hers Health during the second quarter valued at approximately $1,266,000. Stratos Wealth Partners LTD. purchased a new position in Hims & Hers Health during the second quarter valued at approximately $236,000. WealthPlan Investment Management LLC grew its position in Hims & Hers Health by 2.6% during the second quarter. WealthPlan Investment Management LLC now owns 16,404 shares of the company’s stock valued at $818,000 after purchasing an additional 410 shares in the last quarter. Finally, New York State Teachers Retirement System grew its position in Hims & Hers Health by 5.3% in the second quarter. New York State Teachers Retirement System now owns 205,061 shares of the company’s stock worth $10,222,000 after acquiring an additional 10,266 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HIMS. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Canaccord Genuity Group reissued a “buy” rating and issued a $68.00 price target on shares of Hims & Hers Health in a research report on Friday, September 12th. KeyCorp started coverage on shares of Hims & Hers Health in a research report on Tuesday. They issued a “sector weight” rating for the company. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Hims & Hers Health in a research note on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $38.92.

Insider Activity

In related news, insider Soleil Boughton sold 2,637 shares of the firm’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $54.38, for a total transaction of $143,400.06. Following the sale, the insider directly owned 161,130 shares in the company, valued at $8,762,249.40. This trade represents a 1.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Michael Chi sold 900 shares of the firm’s stock in a transaction on Friday, October 10th. The stock was sold at an average price of $58.25, for a total transaction of $52,425.00. Following the sale, the insider owned 291,439 shares in the company, valued at approximately $16,976,321.75. The trade was a 0.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,432,206 shares of company stock valued at $74,248,448. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $48.86 on Friday. Hims & Hers Health, Inc. has a 52-week low of $18.33 and a 52-week high of $72.98. The stock has a market cap of $11.04 billion, a PE ratio of 61.07, a PEG ratio of 3.36 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The firm’s 50 day moving average price is $51.14 and its two-hundred day moving average price is $49.50.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health’s revenue was up 72.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.